Vitality Watch

⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.

Mentioned 1× · first seen 28-sep-2026 · last seen 28-sep-2026

BIRC6 Inhibition (LNP-ASO)

Current understanding

To be populated as evidence accumulates.

Evidence log

  • 2026-09-23 — Targeting BIRC6 rejuvenates hematopoietic stem cell aging and immunosenescence.: Preclinical mouse study plus ex vivo human HSC work: antibody-conjugated LNP-ASOs against BIRC6 disrupt a newly mapped bone-marrow Treg–cAMP–PKA–CREB–BIRC6 axis that shields aged HSCs from apoptosis, reversing HSC aging and immunosenescence in middle-aged mice and showing activity in middle-aged human HSCs. [animal-model] (novelty: 4)

Open questions

Related

Contributing findings

pubmed preclinical animal-model
Targeting BIRC6 rejuvenates hematopoietic stem cell aging and immunosenescence.
23-sep-2026 novelty 4 per-area 4 strengthens

build build 880 · 2bcef25 · 2026-11-18